VEGF (Vascular Endothelial Growth Factor): Complete Research Profile — VEGF-A Isoforms, VEGFR1/2/3 Signaling, Angiogenesis, Lymphangiogenesis, and Anti-VEGF Biologic Research (2026)

# VEGF (Vascular Endothelial Growth Factor): Complete Research Profile — VEGF-A Isoforms, VEGFR1/2/3 Signaling, Angiogenesis, Lymphangiogenesis, and Anti-VEGF Biologic Research (2026)

Vascular endothelial growth factor (VEGF) is one of the most extensively studied growth factors in biomedical research — a secreted glycoprotein family whose members act as master regulators of blood vessel formation, vascular permeability, and lymphatic development. Since the initial identification of "Vascular Permeability Factor" (VPF) by Senger and colleagues in 1983 and the subsequent cloning of VEGF-A by Ferrara and Henzel in 1989, the VEGF family has grown into a sophisticated signaling system spanning five ligands, three receptor tyrosine kinases, and two co-receptors — each with distinct tissue distributions, binding preferences, and biological outputs.

In the laboratory, VEGF peptides and recombinant proteins are indispensable research tools. VEGF-A drives in vitro angiogenesis assays, endothelial tube formation models, and ex vivo aortic ring assays. VEGF-C and VEGF-D power lymphangiogenesis research relevant to cancer metastasis and lymphedema models. Recombinant VEGF-A is a standard supplement in endothelial cell culture, and anti-VEGF monoclonal antibodies serve as both research reagents and the scientific basis for clinically validated biologics like bevacizumab, ranibizumab, and aflibercept.

> Research Use Only (RUO): All VEGF-related peptides and proteins discussed in this article are intended exclusively for laboratory investigation. They are not approved for human or veterinary therapeutic use outside of validated clinical settings.

---

The VEGF Ligand Family: Five Members, Distinct Biology

The mammalian VEGF/PDGF superfamily comprises five homodimeric secreted glycoproteins, each encoded by separate genes and displaying characteristic receptor affinities, tissue expression patterns, and biological functions:

VEGF-A: The Prototype Angiogenic Factor

VEGF-A (encoded by the VEGFA gene on chromosome 6p12) is the founding and most functionally characterized family member. It signals through both VEGFR-1 (FLT-1) and VEGFR-2 (KDR/FLK-1), with the angiogenic response driven predominantly through VEGFR-2.

Alternative splicing creates a complex isoform repertoire. The VEGFA gene spans approximately 16 kb and contains 8 exons. Differential inclusion of exons 6 and 7 (which encode heparin-binding domains) generates isoforms that differ in diffusibility and extracellular matrix (ECM) retention:

• •VEGF-A₁₂₁: Lacks exons 6 and 7; freely diffusible, minimal heparin binding
• •VEGF-A₁₆₅: Includes exon 7 only; the most abundant isoform in most adult tissues; moderate heparin affinity and neuropilin-1 binding
• •VEGF-A₁₈₉: Includes both exons 6 and 7; strongly ECM-bound
• •VEGF-A₂₀₆: All exons included; essentially sequestered in the ECM
• •VEGFₓₓₓb isoforms: Arise from distal splice-site selection in exon 8; these "anti-angiogenic" isoforms antagonize pro-angiogenic VEGFxxx signaling

The VEGF-A₁₆₅/VEGF-A₁₆₅b balance is biologically significant: tumors and ischemic tissue typically shift toward pro-angiogenic isoforms, while quiescent retinal vasculature maintains high levels of the anti-angiogenic VEGF₁₆₅b. This isoform balance has implications for disease modeling and therapeutic targeting.

VEGF-A expression is tightly regulated by hypoxia through the Hypoxia-Inducible Factor-1α (HIF-1α) pathway. Under normoxia, HIF-1α is hydroxylated by prolyl hydroxylases (PHDs), ubiquitinated by VHL E3 ligase, and degraded. Hypoxia inactivates PHDs, stabilizing HIF-1α, which dimerizes with HIF-1β (ARNT) and binds the hypoxia-response element (HRE) in the VEGFA promoter to drive transcription. This HIF→VEGF axis is a central mechanism of tumor angiogenesis and the rationale for HIF-targeting research strategies.

VEGF-B: The Endothelium Survival Factor

VEGF-B (encoded by VEGFB on chromosome 11q13) signals exclusively through VEGFR-1 and neuropilin-1. Despite its restricted expression — predominantly in heart, skeletal muscle, and brown adipose tissue — VEGF-B plays a non-redundant role in:

• •Coronary vessel development and cardiac metabolism
• •Pericyte recruitment and vascular stabilization
• •Fatty acid transport to oxidative tissues via metabolic regulation of endothelial lipid uptake

Unlike VEGF-A, VEGF-B does not strongly induce vascular permeability, and its angiogenic activity is context-dependent — making it a subject of interest in metabolic and cardiac research models.

VEGF-C: The Lymphangiogenic Master Regulator

VEGF-C (encoded by VEGFC on chromosome 4q34) is the primary driver of lymphatic vessel formation. It undergoes proteolytic processing from a 60 kDa pro-protein to a ~29 kDa mature form, with intermediate forms displaying distinct receptor binding profiles:

• •Unprocessed/partially processed VEGF-C: Binds VEGFR-3 with high affinity; drives lymphangiogenesis
• •Fully mature VEGF-C: Gains the ability to activate VEGFR-2; can also induce angiogenesis

This processing-dependent signaling switch makes VEGF-C uniquely versatile. In tumors, cancer cells secrete VEGF-C to induce peritumoral lymphangiogenesis, which facilitates lymphatic metastasis — a phenomenon now recognized as a distinct therapeutic target.

VEGF-D: The Lymphatic Expansion Factor

VEGF-D (encoded by VEGFD on chromosome Xp22.31) shares ~48% amino acid identity with VEGF-C and undergoes similar proteolytic maturation. Mature VEGF-D activates both VEGFR-2 and VEGFR-3, making it a dual promoter of angiogenesis and lymphangiogenesis. In human tissues, VEGF-D expression is widespread, with particularly high levels in lung, heart, and skeletal muscle. It has been explored as a marker in cancer research due to its association with lymph node involvement.

PlGF (Placental Growth Factor): The Context-Dependent Modulator

PlGF (encoded by PGF on chromosome 14q24) signals exclusively through VEGFR-1 and neuropilin-1. It exists in four splice isoforms (PlGF-1 through PlGF-4) with varying heparin-binding capacities. PlGF is largely dispensable in healthy adults but becomes critical in pathological states:

• •PlGF is dramatically upregulated during pregnancy (hence its name), ischemia, inflammation, and tumor development
• •PlGF can displace VEGF-A from VEGFR-1, effectively increasing free VEGF-A available for VEGFR-2 signaling (a "decoy receptor" displacement mechanism)
• •PlGF/VEGFR-1 signaling activates macrophages and recruits bone marrow-derived cells to sites of pathological angiogenesis
• •Notably, serum PlGF is being investigated as a diagnostic biomarker for preeclampsia

---

VEGF Receptors: Three RTKs, Two Co-Receptors

VEGFR-1 (FLT-1): The Decoy and Context-Dependent Activator

VEGFR-1 (FMS-like tyrosine kinase-1, encoded by FLT1 on chromosome 13q12) is a paradoxical receptor. Despite binding VEGF-A, VEGF-B, and PlGF with higher affinity than VEGFR-2 (~10x greater affinity for VEGF-A), its intrinsic kinase activity is weak, and it generates relatively low downstream signaling. This has led to the "decoy receptor" model: VEGFR-1 may primarily sequester VEGF-A away from the highly signaling-competent VEGFR-2 to fine-tune the magnitude of the angiogenic response.

However, VEGFR-1 is not entirely passive. In macrophages, monocytes, and hematopoietic precursors, VEGFR-1 activation drives chemotaxis and mobilization — contributing to the inflammatory and bone marrow-derived cell component of tumor angiogenesis. A naturally occurring soluble splice variant, sFLT-1, retains the VEGF-binding extracellular domain but lacks the transmembrane and kinase domains, functioning as an endogenous anti-angiogenic decoy. sFLT-1 is produced by endothelial cells and placental syncytiotrophoblasts, and its dysregulation is mechanistically linked to preeclampsia.

Ligand specificity: VEGF-A, VEGF-B, PlGF

VEGFR-2 (KDR/FLK-1): The Primary Angiogenic Signal Transducer

VEGFR-2 (kinase insert domain receptor, KDR in humans; fetal liver kinase 1, Flk1 in mice) is the dominant mediator of VEGF-driven angiogenesis, vascular permeability, endothelial proliferation, migration, and survival. Its high intrinsic kinase activity — in contrast to VEGFR-1 — makes it the functional workhorse of the VEGF system.

Receptor activation mechanism: VEGF-A₁₆₅ binding induces VEGFR-2 dimerization and trans-autophosphorylation at multiple tyrosine residues:

VEGFR-2 → PLCγ → PKC → MAPK (ERK1/2) is the predominant proliferation signal. VEGFR-2 → PI3K → Akt → eNOS drives endothelial nitric oxide (NO) production, vascular dilation, and permeability. VEGFR-2 → Src → VE-cadherin phosphorylation destabilizes adherens junctions and increases paracellular permeability, a mechanism relevant to tumor microenvironment research.

Ligand specificity: VEGF-A (primary), VEGF-E (viral VEGF homologs), mature VEGF-C and VEGF-D

VEGFR-3 (FLT-4): The Lymphangiogenic Receptor

VEGFR-3 (FLT-4, encoded by FLT4 on chromosome 5q35.3) is the primary driver of lymphatic endothelial biology. In embryonic development, VEGFR-3 is initially expressed on all vascular endothelium but becomes restricted to lymphatic endothelial cells (LECs) postnatally. Germline mutations in FLT4 cause hereditary lymphedema (Milroy's disease), demonstrating its non-redundant role in lymphatic vessel maintenance.

VEGFR-3 signaling activates MAPK/ERK and PI3K/Akt pathways to promote LEC proliferation, migration, and survival. Its activation by VEGF-C and VEGF-D is required for tumor lymphangiogenesis and sentinel lymph node involvement — a mechanism central to current research on metastatic routes.

Ligand specificity: VEGF-C, VEGF-D (primary); VEGF-A in certain contexts

Neuropilins (NRP1, NRP2): The Co-Receptors

Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) are transmembrane glycoproteins that lack intrinsic kinase activity but serve as essential co-receptors that enhance VEGFR signaling:

• •NRP1: Binds VEGF-A₁₆₅ (via its exon-7-encoded heparin-binding domain) and forms a complex with VEGFR-2, significantly enhancing signaling potency. NRP1 also mediates VEGF-A arterial specification through a VEGFR-2-independent mechanism involving PlGF.
• •NRP2: Primarily expressed on lymphatic endothelium; acts as co-receptor for VEGF-C/VEGFR-3 to enhance lymphangiogenic signaling.

The NRP1/VEGFR-2 complex is of particular research interest because it can explain why isoform-specific VEGF targeting (e.g., targeting only VEGF-A₁₆₅ while sparing VEGF-A₁₂₁) can have differential effects on vessel morphology versus permeability.

---

VEGF in Biological Processes: Research Contexts

Tumor Angiogenesis: The Warburg-to-VEGF Connection

The "angiogenic switch" — the transition from dormant avascular tumor nodules to actively vascularized tumors — is one of the hallmark mechanisms of cancer progression (Hanahan & Weinberg, 2011). VEGF-A overexpression, driven by HIF-1α under the hypoxic microenvironment of tumors, is a near-universal feature of solid tumors. This established the scientific rationale for bevacizumab (anti-VEGF-A antibody) as the first anti-angiogenic cancer biologic, approved by the FDA in 2004.

Research findings from tumor angiogenesis models include:

• •Vessel normalization: Anti-VEGF therapy in preclinical models can paradoxically improve intratumoral drug delivery by "normalizing" the chaotic tumor vasculature, reducing interstitial fluid pressure
• •Resistance mechanisms: Tumors develop resistance to anti-VEGF therapy via FGF-2 upregulation, c-Met activation, and pericyte-driven vessel maturation that reduces VEGF dependence
• •Tip-stalk cell dynamics: VEGF-A gradients govern the "tip cell" (migrating, invasive) versus "stalk cell" (proliferating, lumen-forming) decision through DLL4/Notch lateral inhibition — a key area of current anti-angiogenic research

Ocular Neovascularization Research

The eye is a unique research model for VEGF biology because of its immune privilege, accessibility, and the availability of validated outcome measures. Key areas:

• •Neovascular AMD (nAMD): Choroidal neovascularization (CNV) in the subretinal space is driven by VEGF-A overexpression and is the target of intravitreal anti-VEGF injections — now standard clinical research models
• •Diabetic Retinopathy (DR): Retinal ischemia upregulates VEGF-A via HIF-1α, driving pre-retinal neovascularization. The retinal VEGF₁₂₁/VEGF₁₆₅ balance and VEGF₁₆₅b anti-angiogenic isoforms are of particular interest
• •Retinopathy of Prematurity (ROP): Oxygen fluctuations in premature neonates trigger pathological VEGF-driven retinal neovascularization — a model with implications for both ocular and developmental vascular biology research

Wound Healing and Tissue Repair Research

VEGF-A is a crucial mediator of the proliferative phase of wound healing. Following injury, platelet degranulation releases preformed VEGF-A, and subsequently, macrophages, keratinocytes, and fibroblasts upregulate VEGF-A transcription in response to hypoxia, TGF-β, and PDGF. This drives re-vascularization of the wound bed.

In chronic wound research models, VEGF-A levels are often paradoxically low in the wound fluid despite systemic upregulation, possibly due to:

• •Proteolytic degradation of VEGF-A by matrix metalloproteinases (MMPs)
• •Sequestration of VEGF-A by elevated sFLT-1
• •Defective HIF-1α stabilization in diabetic tissue

Controlled delivery of VEGF-A or VEGF-C using hydrogels, nanoparticles, or fibrin scaffolds is an active area of tissue engineering research.

Lymphedema and Lymphangiogenesis Research

VEGF-C and VEGF-D/VEGFR-3 axis research is particularly active given the clinical burden of lymphedema (post-cancer treatment and primary hereditary forms). Key research findings:

• •VEGF-C gene delivery in preclinical lymphedema models induces functional lymphatic regeneration (Tammela et al., 2007, Nature Medicine)
• •VEGFR-3 signaling drives the "stalk-to-tip" decision in lymphatic sprouting, mirroring the role of VEGFR-2 in blood vessel angiogenesis
• •The CCBE1 protein (collagen and calcium binding EGF domain-containing protein 1) and ADAMTS3 protease are required for full VEGF-C processing and VEGFR-3 activation — a discovery that revealed new therapeutic entry points

Cardiac and Ischemia Research

The therapeutic potential of VEGF in ischemic disease has driven extensive preclinical research:

• •Myocardial ischemia: Intramyocardial VEGF-A delivery in rodent and large animal models promotes collateral vessel formation, improving regional blood flow and function
• •VEGF-B and cardiac metabolism: VEGF-B regulates fatty acid uptake into cardiomyocytes via endothelial transport mechanisms, making it a unique research target in cardiac metabolic diseases distinct from angiogenic effects
• •Critical limb ischemia (CLI): VEGF gene therapy and protein delivery have shown therapeutic angiogenesis in preclinical models, though clinical translation has faced challenges related to delivery, biodistribution, and sustained expression

---

Anti-VEGF Research Tools and Biologics

The VEGF system is one of the most drug-targeted pathways in modern medicine. Understanding the mechanisms of these agents provides critical context for VEGF research design:

Bevacizumab (Avastin)

Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds all isoforms of VEGF-A with high affinity (Kd ~1 pM), preventing receptor binding. It was the first clinically approved anti-VEGF agent (FDA, 2004) for colorectal cancer, and has since been approved for NSCLC, glioblastoma, renal cell carcinoma, and cervical cancer.

In research contexts, bevacizumab is used as a validated anti-angiogenic control in preclinical angiogenesis assays, a tool to delineate VEGF-A-dependent versus -independent angiogenesis, and as the reference molecule for biosimilar development research.

Ranibizumab (Lucentis)

Ranibizumab is a humanized anti-VEGF-A Fab fragment developed specifically for ocular use (smaller size for better vitreous penetration and retinal bioavailability). It binds all VEGF-A isoforms and is approved for nAMD, macular edema, and retinal vein occlusion.

Aflibercept (Eylea, Zaltrap)

Aflibercept is a fusion protein combining the VEGF-binding domains of VEGFR-1 (Ig domain 2) and VEGFR-2 (Ig domain 3) fused to an IgG1 Fc region. This "VEGF Trap" design confers higher affinity for VEGF-A (Kd ~0.5 pM, approximately 100-fold higher than bevacizumab) and additionally captures PlGF and VEGF-B — a broader binding profile that may be relevant in pathologies where PlGF contributes to angiogenesis.

Small Molecule VEGFR Inhibitors

While not peptide-based, the following small molecule tyrosine kinase inhibitors (TKIs) target VEGFR and are important comparative tools in research:

• •Sunitinib: Multi-target TKI (VEGFR-1/2/3, PDGFR, RET, KIT); used as research reference for pan-VEGFR inhibition
• •Sorafenib: VEGFR-2/3, PDGFR-β, RAF; used in hepatocellular carcinoma models
• •Axitinib: Highly selective VEGFR-1/2/3 inhibitor; useful for VEGFR-pathway-specific research questions
• •Pazopanib, Cabozantinib, Lenvatinib: Approved multi-target TKIs with varying VEGFR selectivity profiles

Anti-VEGF-C/VEGFR-3 Research Agents

• •VGX-100 (anti-VEGF-C antibody): Research-phase agent that specifically blocks VEGF-C/VEGFR-3 without affecting blood vessel VEGF-A/VEGFR-2 signaling — a valuable research tool for dissecting lymphangiogenesis
• •SAR131675 (VEGFR-3 kinase inhibitor): Research compound for selective VEGFR-3 blockade in lymphangiogenesis models

---

VEGF in Disease Research: Quantification and Biomarker Studies

VEGF-A is routinely measured in research models as a biomarker of angiogenic activity. Key methodological considerations for laboratory research:

ELISA and Multiplex Quantification

• •Free VEGF-A vs. total VEGF-A assays capture different pools: free VEGF quantifies signaling-available ligand, while total VEGF captures both free and receptor/matrix-bound forms
• •Serum VEGF-A concentrations in healthy subjects: typically 50–450 pg/mL, but these vary considerably by platelet count (platelets store significant VEGF-A) — EDTA plasma is preferred for circulating VEGF-A research
• •PlGF is being investigated as a biomarker for preeclampsia risk stratification (sFlt-1/PlGF ratio) and placental dysfunction models

In Vitro Angiogenesis Assays

Standard VEGF-driven research assays include:

• •Endothelial tube formation assay (Matrigel): VEGF-A₁₆₅ at 10–50 ng/mL is the standard stimulus; VEGFR2 inhibitors (SU1498, ZM323881) serve as negative controls
• •Scratch/wound migration assay: VEGF-A₁₆₅ stimulates endothelial migration via VEGFR-2/PI3K/Akt signaling
• •Aortic ring assay: Ex vivo model using mouse or rat aorta rings embedded in collagen/Matrigel; outgrowth is driven endogenously and can be supplemented with VEGF-A or inhibited by anti-VEGF agents
• •Spheroid sprouting assay: Endothelial cell spheroids stimulated with VEGF-A to model sprouting angiogenesis with tip/stalk cell dynamics

Mouse Matrigel Plug Assay

In vivo angiogenesis research model: Matrigel supplemented with VEGF-A is injected subcutaneously; blood vessel ingrowth is quantified histologically or via hemoglobin measurement. This model is widely used to test anti-angiogenic compounds.

---

Key PubMed References for VEGF Research

The following are landmark and recent citations relevant to VEGF research:

1. Ferrara N, Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 161(2):851-858. PMID: 2735925 — The original VEGF cloning paper.

2. Leung DW, et al. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246(4935):1306-1309. PMID: 2479986 — VEGF characterization.

4. Shibuya M (2011). Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer, 2(12):1097-1105. PMID: 22866201 — VEGFR signaling mechanisms.

5. Tammela T, et al. (2007). Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med, 13(12):1458-1466. PMID: 18059280 — VEGF-C in lymphedema.

6. Apte RS, Chen DS, Ferrara N (2019). VEGF in signaling and disease: beyond discovery and development. Cell, 176(6):1248-1264. PMID: 30849371 — State-of-the-field VEGF review.

7. Rankin EB, Giaccia AJ (2016). Hypoxic control of metastasis. Science, 352(6282):175-180. PMID: 27124451 — HIF-VEGF axis and tumor biology.

8. Olsson AK, et al. (2006). VEGF receptor signalling — in control of vascular function. Nat Rev Mol Cell Biol, 7(5):359-371. PMID: 16633338 — VEGFR signal transduction review.

---

VEGF Research Summary

---

Conclusion

The VEGF family represents one of the most pharmacologically tractable signaling systems in biology. From the original discovery of VPF/VEGF as a tumor-secreted permeability factor to the current generation of multi-target VEGFR inhibitors and bispecific antibodies, VEGF research has yielded transformative scientific insights and clinically validated therapeutic strategies.

For laboratory investigators, the VEGF system offers a well-characterized framework for studying fundamental vascular biology processes — angiogenesis, permeability, tip/stalk cell specification, and lymphangiogenesis — while simultaneously providing a direct translational bridge to validated anti-angiogenic and pro-vascular research programs. Recombinant VEGF-A₁₆₅, VEGF-C, and the range of VEGFR-targeting research tools enable precise dissection of each arm of this system, supporting research from basic endothelial cell culture to complex in vivo tumor and ischemia models.

---

All information is provided for research and educational purposes only. VEGF peptides and proteins are Research Use Only (RUO) materials intended exclusively for laboratory investigation.